NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Leukaemia (chronic myeloid) - bosutinib NICE TAG TA299

Leukaemia (chronic myeloid) - bosutinib NICE TAG TA299

1.1 Bosutinib is not recommended within its marketing authorisation for treating Philadelphia‑chromosome‑positive chronic myeloid leukaemia (CML).

1.2 People currently receiving bosutinib that is not recommended for them in NICE guidance should be able to continue treatment until they and their clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/TA299

Site by Devopa
© Copyright 2019 NHS. All rights reserved.